Ligand Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is February - January.

Millions USD. Fiscal year is Feb - Jan.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Jan '25 Jan 31, 2025	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022	Jan '21 Jan 31, 2021	2016 - 2020
Revenue	2,747	2,364	2,155	1,851	1,465	Upgrade
Revenue Growth (YoY)	16.20%	9.68%	16.44%	26.33%	32.70%	Upgrade
Cost of Revenue	699.64	677.29	609.41	503.68	408.93	Upgrade
Gross Profit	2,047	1,686	1,546	1,347	1,056	Upgrade
Selling, General & Admin	657.47	628.02	566.29	459.57	384.13	Upgrade
Research & Development	693.08	629.03	520.28	382.04	294.22	Upgrade
Operating Expenses	1,351	1,257	1,087	841.6	678.35	Upgrade
Operating Income	696.44	429.33	459.09	505.5	377.79	Upgrade
Interest & Investment Income	207.99	133.75	45.86	14.73	15.86	Upgrade
Currency Exchange Gain (Loss)	-3.27	0.12	0.59	-0.71	2.28	Upgrade
Other Non Operating Income (Expenses)	0.61	-	0.57	-	1.15	Upgrade
EBT Excluding Unusual Items	901.76	563.21	506.11	519.51	397.08	Upgrade
Gain (Loss) on Sale of Investments	22.62	24.82	2.98	-7.2	-3.08	Upgrade
Legal Settlements	-5	-	-	-	-	Upgrade
Pretax Income	919.38	588.02	509.1	512.31	393.99	Upgrade
Income Tax Expense	205.24	62.32	21.39	84.92	14	Upgrade
Net Income	714.14	525.71	487.71	427.39	380	Upgrade
Net Income to Common	714.14	525.71	487.71	427.39	380	Upgrade
Net Income Growth	35.84%	7.79%	14.11%	12.47%	26.20%	Upgrade
Shares Outstanding (Basic)	162	161	155	153	151	Upgrade
Shares Outstanding (Diluted)	165	163	162	162	161	Upgrade
Shares Change (YoY)	1.07%	0.65%	0.10%	0.96%	1.54%	Upgrade
EPS (Basic)	4.41	3.27	3.14	2.79	2.52	Upgrade
EPS (Diluted)	4.32	3.22	3.00	2.63	2.36	Upgrade
EPS Growth	34.16%	7.33%	14.07%	11.44%	24.21%	Upgrade
Free Cash Flow	1,070	885.14	766.96	750.25	542.56	Upgrade
Free Cash Flow Per Share	6.47	5.41	4.72	4.62	3.38	Upgrade
Gross Margin	74.53%	71.35%	71.72%	72.79%	72.09%	Upgrade
Operating Margin	25.36%	18.16%	21.30%	27.31%	25.79%	Upgrade
Profit Margin	26.00%	22.24%	22.63%	23.09%	25.94%	Upgrade
Free Cash Flow Margin	38.94%	37.45%	35.59%	40.54%	37.03%	Upgrade
EBITDA	735.82	461.96	488.21	532.94	407.25	Upgrade
EBITDA Margin	26.79%	19.54%	22.65%	28.80%	27.80%	Upgrade
D&A For EBITDA	39.38	32.63	29.12	27.45	29.46	Upgrade
EBIT	696.44	429.33	459.09	505.5	377.79	Upgrade
EBIT Margin	25.36%	18.16%	21.30%	27.31%	25.79%	Upgrade
Effective Tax Rate	22.32%	10.60%	4.20%	16.58%	3.55%	Upgrade
Revenue as Reported	2,747	2,364	2,155	1,851	1,465	Upgrade

Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.